Navigation Links
Topiramate Exposure and Birth Defect Data to be Presented at the 29th International Epilepsy Congress
Date:7/20/2011

A(3)Columbia Comprehensive Epilepsy Center, New York, United States, (2)Emory University, Atlanta, United States, (3)Wolters Kluwer Pharma Solutions, Yardley, United States
Poster Session: Late Submissions
Poster #: 866
Time: 1:00-2:30 local time

About QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors, when used in combination with a diet and lifestyle modification program.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use o
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
2. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
3. Upsher-Smith Laboratories Announces Initiation of Open-Label Extension Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
4. Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate
5. FDA: Risk of Oral Birth Defects in Children Born to Mothers Taking Topiramate
6. Phase I Research of Extended-Release Topiramate Shows Less Fluctuation in Plasma Levels
7. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference
10. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
11. Two New Clinical Studies Show That Limited Exposure to Blood Transfusion Significantly Increases Morbidity and Mortality After Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  Medimetriks Pharmaceuticals, Inc. announced ... Phase III clinical study for Ozenoxacin, a novel ... owns the exclusive U.S. rights to Ozenoxacin 1% ... at 44 centers with an emphasis on U.S. ... 2 months and older with a clinical diagnosis ...
(Date:7/30/2015)... SAN FRANCISCO , July 30, 2015 ... devices market is expected to reach USD 23.01 ... Grand View Research, Inc. Growing base of geriatric population, ... and infections, and rising level of awareness among target ... impact rendering drivers over the forecast period. According to ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... of Iomai Adjuvant ... Patch -, ... announced that it has begun dosing in a Phase 1/2,study that will ... in combination with an injected,H5N1 influenza vaccine. The Iomai patch, which ...
... Biopure Corporation,(Nasdaq: BPUR ) today announced that it ... use protocol submitted by the company in July. At,the ... for a Phase,2 randomized trial for the treatment of ... alloantibody anemia but,excluding sickle cell anemia. Hemopure has been ...
Cached Medicine Technology:Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 2Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 3Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine 4Biopure Reports on Meeting with the FDA 2Biopure Reports on Meeting with the FDA 3
(Date:7/30/2015)... ... July 30, 2015 , ... Glidewell Laboratories, industry-leading provider of ... magazine, its multimedia publication focused on implant dentistry, is now available in print ... 6, Issue 2, as well as past issues of the dental laboratory’s quarterly ...
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students ... World Games, the largest sports and humanitarian event in the world this year and ... World Games, held July 25 through August 2, 2015, benefited from the participation of ...
(Date:7/30/2015)... , ... July 30, 2015 , ... On July 23rd ... billion in taxpayer money to fund the state’s large prison system, which has amassed ... the highest rates of incarceration. In light of President Obama’s recent reduction of non ...
(Date:7/30/2015)... ... July 30, 2015 , ... Quintessa Medical Spa is happy to offer patients ... designed specifically for the elimination of excess tissue under the chin, referred to ... state of Wisconsin to offer this innovative treatment. , Developed by Kythera Biopharmaceuticals, Kybella ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... Gummy ... including lip lowering, gum contouring and surgery, as well as the patented gum depigmentation ... that has made him popular with many patients from around the world. , “Like ...
Breaking Medicine News(10 mins):Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2
... Researchers at the Food Technology Plant Special Research Centre ... celiac disease// otherwise called as gluten sensitive enteropathy. This ... known to have enhanced nutritive value and increased shelf ... of gluten, forcing sufferers to follow a strictly gluten-free ...
... plenty of good reasons, the term “trans fat” leaves ... Typically, trans fatty acids are bad for health, but// ... have coaxed out significant health benefits by juggling the ... professor of food science, and graduate student Vishal Jain ...
... today urged Australians to spare a thought this week for ... time of year for most people means joyful gatherings with ... and despair,' Dr Yong said. ,'The social circuit, ... can cause depression for those who are socially isolated. ...
... obstinate, as scientists have discovered, as they portray a ... extremely// difficult to annihilate. In fact radiation could even ... from the University of California, Los Angeles, who are ... cells that get radiation resistant and render breast cancer ...
... producing cane sugar with lower glycaemic index (GI) that it ... ranking system for carbohydrates based on their immediate effect on ... risk of diabetes because they trigger rapid increases in blood ... ,The sugar, developed by firm 'Horizon Science of ...
... 'DNA-diets', advertised extensively on the internet, making tall claims of ... ,A study, spearheaded by researchers at the Economic and Social ... University of Exeter, is the first study of its kind ... diets are also called 'nutrigenomic' diets that are customized diet ...
Cached Medicine News:Health News:Gluten Free Bread: Boon for Celiac Disease 2Health News:Healthy Potato Chips: A Trans Fat Oil With Health Benefits 2
... implanted bone growth stimulator for the treatment ... implanted bone growth stimulator is a useful ... surgery is already planned or when patient ... OsteoGen is totally surgically implanted, patients are ...
... Stryker is proud to offer ... on the market at only ... design incorporates a superior flow ... intuitive locking mechanisms. The complementing ...
... Cryocare® CS is ... placement and treatment system ... and allow unlimited flexibility. ... to meet specific physician ...
Sterile Disposable Thermal Cautery Tips for Vasectomy. Individually peel-pouched with dual plastic sheaths to cover non-sterile handle. Box of 10 tips....
Medicine Products: